Lv3
310 积分 2025-06-27 加入
Induction with MEDA regimen and consolidation with Auto‐HSCT for stage IV NKTCL patients: A prospective multicenter study
3个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
4个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
4个月前
已完结
Germ layer specification and organotropism in lymphoma invasion
5个月前
已完结
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
8个月前
已完结
P-071 Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium
8个月前
已完结
Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma
9个月前
已完结
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
10个月前
已完结
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial
10个月前
已完结
Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis
10个月前
已完结
皖公网安备34019202002308
